

REMARKS

I. RESPONSE TO RESTRICTION REQUIREMENT

1. In response to the Restriction Requirement, Applicants elect Group I without traverse. Applicants reserve the right to pursue claims drawn to the subject matter of Groups II-V in one or more divisional application(s).

2. With respect to the election of species requirements set forth at pages 4-7 of the Office Action (items 3 and 4 of the Office Action), Applicants elect the species Acetaminophen and liver necrosis, without traverse.

However, Applicants respectfully request that additional toxic effects recited in dependent claims 20, 21 and 66-68 (“carcinogenesis, cholestasis, hepatitis, liver enlargement, inflammation, liver necrosis, liver steatosis, and peroxisome proliferation”) be searched in this application.

Applicants also respectfully request that additional hepatotoxins recited in dependent claims 22, 47 and 69 (“acetaminophen, 2-acetylaminofluorene (2-AAF), acyclovir, ANIT, AY-25329, BI liver toxin, chloroform, bicalutamide, carbon tetrachloride, chloroform, CI-1000, clofibrate, colchicine, CPA, diclofenac, diflunisal, dimethylnitrosamine (DMN), dioxin, 17 α -ethynodiol, gemfibrozil, hydrazine, indomethacin, LPS, menadione, phenobarbital, tacrine, thioacetamide, valproate, Wy-14643 and zileuton”) be searched in this application.

3. In response to the gene election requirement at page 3 of the Office Action, Applicants elect the following sequences (one from each of Tables 5A-5WWW as suggested by the Examiner at page 4 of the Office Action) with traverse:

| TABLE 5 | GLGC ID | SEQ ID NO |
|----------------|----------------|------------------|
| A | 24237 | 130 |
| B | 2459 | 1089 |
| C | 17361 | 365 |
| D | 24437 | 3304 |
| E | 2515 | 2995 |
| F | 10611 | 2278 |
| G | 20818 | 4184 |
| H | 21051 | 2839 |

| | | |
|-----|-------|------|
| I | 4234 | 3626 |
| J | 21848 | 3932 |
| K | 15127 | 3879 |
| L | 9128 | 2100 |
| M | 573 | 2558 |
| N | 1794 | 3221 |
| O | 20589 | 3097 |
| P | 16457 | 3961 |
| Q | 14664 | 4031 |
| R | 14664 | 4031 |
| S | 1698 | 3247 |
| T | 9348 | 1740 |
| U | 17758 | 3958 |
| V | 22852 | 2346 |
| W | 3431 | 2218 |
| X | 15987 | 420 |
| Y | 2084 | 1165 |
| Z | 21968 | 954 |
| AA | 21968 | 954 |
| BB | 2248 | 2046 |
| CC | 2248 | 2046 |
| DD | 21098 | 3968 |
| EE | 13222 | 1824 |
| FF | 14595 | 536 |
| GG | 12306 | 891 |
| HH | 6143 | 3912 |
| II | 10611 | 2278 |
| JJ | 9604 | 1700 |
| KK | 9604 | 1700 |
| LL | 23699 | 3058 |
| MM | 23710 | 3223 |
| NN | 20864 | 3236 |
| OO | 2088 | 2472 |
| PP | 14887 | 2725 |
| QQ | 14887 | 2725 |
| RR | 24300 | 2399 |
| SS | 21874 | 2693 |
| TT | 12160 | 168 |
| UU | 20744 | 3083 |
| VV | 14124 | 371 |
| WW | 14033 | 1434 |
| XX | 23698 | 3058 |
| YY | 17758 | 3958 |
| ZZ | 23262 | 2393 |
| AAA | 23262 | 2393 |
| BBB | 22370 | 864 |
| CCC | 4196 | 685 |
| DDD | 12160 | 168 |
| EEE | 4011 | 3643 |
| FFF | 20983 | 1566 |
| GGG | 22929 | 1709 |

| | | |
|-----|-------|------|
| HHH | 20741 | 1241 |
| III | 6532 | 2654 |
| III | 20529 | 3309 |
| KKK | 22840 | 1325 |
| LLL | 20915 | 3472 |
| MMM | 4011 | 3643 |
| NNN | 15606 | 877 |
| OOO | 1246 | 3024 |
| PPP | 2485 | 142 |
| QQQ | 2485 | 142 |
| RRR | 18742 | 1886 |
| SSS | 20915 | 3472 |
| TTT | 23710 | 3223 |
| UUU | 15125 | 3879 |
| VVV | 22929 | 1709 |
| WWW | 18564 | 3171 |

This requirement is being traversed because a restriction on the basis of individual sequences is not warranted here under the unity of invention standards (the present application being a national stage application of PCT/US03/03194), especially in light of the election of species requirement. The Examiner is respectfully requested to search the claims on the basis of the species election set forth above (e.g., the toxic effect and hepatotoxin).

In addition, the claims have been amended to more clearly set forth the unity of invention, as discussed further below.

II. AMENDMENTS TO THE CLAIMS

In this Amendment: claims 1, 3-5, 7-10, 20-22, 46-49, 53-56, and 61 are amended; claims 2, 6, 11, 18, 19, 23-45, 50-52, 57, and 62-65 are canceled; and claims 66-69 are new.

Claims 11, 22, 23-45, 47, 50-52, 57-60, 64, and 65, which are drawn to a non-elected invention, are being canceled without prejudice. Applicants reserve the right to pursue the subject matter of these claims in one or more divisional applications.

Independent claim 1 has been amended to more clearly define the unity of invention. The amendments to claim 1 are supported by at least: paragraphs [0005], [0006], and [0012] of the application as filed; paragraph [0187] and original claim 3; as well as original claim 19.

Additional amendments have been made to the claims to clarify the subject matter thereof.

New claims 66-69 parallel original claims 20 and 47, and are being added to facilitate examination in accordance with the election of species requirement.

No new matter has been introduced.

Entry and consideration of this Amendment are requested.

The Examiner is invited to contact the undersigned for resolution of any issues that may arise during prosecution of this application.


Please charge the fee for a one-month extension of time to Deposit Account 50-1283.
Please also credit any overpayments to Deposit Account 50-1283.

Dated: June 26, 2007

COOLEY GODWARD KRONISH LLP
ATTN: Patent Group
1200 19th Street, NW, 5th Floor
Washington, DC 20036
Tel: (202) 842-7800
Fax: (202) 842-7899

By:

Respectfully submitted,
COOLEY GODWARD KRONISH LLP


Mark L. Heyman
Reg. No 51,793